TY - JOUR AU - SHAIKH, ZEESHAN PY - 2019/07/15 Y2 - 2024/03/29 TI - DESIGN AND DEVELOPMENT OF TOPICAL HYDROGEL FORMULATION OF IRBISARTAN JF - International Journal of Current Pharmaceutical Research JA - Int J Curr Pharm Sci VL - 11 IS - 4 SE - Original Article(s) DO - 10.22159/ijcpr.2019v11i4.34924 UR - https://journals.innovareacademics.in/index.php/ijcpr/article/view/34924 SP - 79-83 AB - <p><strong>Objective: </strong>Irbesartan is an antihypertensive with limited bioavailability. The objective of the study was to develop controlled release matrix tablets of irbisartan drug.</p><p><strong>Methods: </strong>Tablets were prepared by wet granulation process. Result: <em>In vitro</em> drug release study revealed that HPMC causes initial burst release of drug hence combining HPMC sustained the action for 8 h (95.92±0.57% release). Fitting the <em>in vitro</em> drug release data to Korsmeyer equation indicated that diffusion along with erosion could be the mechanism for drug release. Compared to conventional tablets, the release of model drug from these HPMC matrix tablets was prolonged, leading to achieve an effective therapy with a low dosage of the drug, to reduce the frequency of medication.<strong> T</strong>he pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension.</p><p><strong>Results: </strong>Compatibility Studies In order to investigate the possible interactions between irbesartan and distinct polymers and/or diluents, FT-IR and DSC studies were carried out. FT-IR results proved that the drug was found to be compatible with excipients as wave numbers are almost similar for pure drug and also drug excipients mixture. In picture 1 and 2. DSC studies indicate that chosen excipients for the formulation were found to be compatible with the active ingredient as the melting endothermic peaks are in the range of 250-320 °C which is same as the melting point of irbisartan.</p><p><strong>Conclusion: </strong>Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150–300 mg once daily confers a lasting effect over 24 h, and its antihypertensive efficacy is further enhanced by the coadministration of hydrochlorothiazide.</p> ER -